

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199719411 B2
(10) Patent No. 715822

(54) Title
Tissue adhesive applied with spray

(51)⁶ International Patent Classification(s)
A61L 025/00 A61B 017/00

(21) Application No: **199719411**

(22) Application Date: **1997.03.14**

(87) WIPO No: **WO97/33633**

(30) Priority Data

(31) Number	(32) Date	(33) Country
8-87566	1996.03.15	JP

(43) Publication Date : **1997.10.01**

(43) Publication Journal Date : **1997.11.27**

(44) Accepted Journal Date : **2000.02.10**

(71) Applicant(s)
Juridical Foundation The Chemo-Sero- Therapeutic Research Institute

(72) Inventor(s)
**Takanori Uchida; Hiroshi Kaetsu; Nobuto Fukunaga; Noriko Shinya;
Takahiro Sakamoto**

(74) Agent/Attorney
COLLISON and CO,GPO Box 2556,ADELAIDE SA 5001

(56) Related Art
US 4427650

PCT

OPI DATE 01/10/97 APPLN. ID 19411/97
AOJP DATE 27/11/97 PCT NUMBER PCT/JP97/00818

AU9719411

(51) 国際特許分類6 A61L 25/00, A61B 17/00	A1	(11) 国際公開番号 WO97/33633 (43) 国際公開日 1997年9月18日(18.09.97)
(21) 国際出願番号 PCT/JP97/00818 (22) 国際出願日 1997年3月14日(14.03.97) (30) 優先権データ 特願平8/87566 1996年3月15日(15.03.96) JP (71) 出願人 (米国を除くすべての指定国について) 財団法人 化学及血清療法研究所 (JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE)[JP/JP] 〒860 熊本県熊本市大窪1丁目6番1号 Kumamoto, (JP) (72) 発明者 ; および (75) 発明者 / 出願人 (米国についてののみ) 内田隆徳(UCHIDA, Takanori)[JP/JP] 〒861-55 熊本県熊本市西梶尾町574-3 Kumamoto, (JP) 嘉悦 洋(KAETSU, Hiroshi)[JP/JP] 〒861-11 熊本県菊池郡西合志町須屋2034-17 Kumamoto, (JP) 福永信人(FUKUNAGA, Nobuto)[JP/JP] 〒865 熊本県玉名市松木16-8 Kumamoto, (JP) 新屋希子(SHINYA, Noriko)[JP/JP] 〒860 熊本県熊本市御領5丁目9番80-102 Kumamoto, (JP)		坂本隆弘(SAKAMOTO, Takahiro)[JP/JP] 〒861-11 熊本県菊池郡合志町豊岡2000-1329 Kumamoto, (JP) (74) 代理人 弁理士 中村 稔, 外(NAKAMURA, Minoru et al.) 〒100 東京都千代田区丸の内3丁目3番1号 新東京ビル646号 Tokyo, (JP) (81) 指定国 AU, CA, JP, KR, US, 欧州特許 (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). 添付公開書類 国際調査報告書
(54) Title: TISSUE ADHESIVE APPLIED WITH SPRAY (54) 発明の名称 スプレー塗布用組織接着剤 (57) Abstract A tissue adhesive capable of forming fibrins uniformly at high density, and exhibiting marked closing effect. This tissue adhesive is mixed with an aseptic gas and the mixture is applied to tissue. The tissue adhesive comprises separated fibrinogen solution and thrombin solution. The volume ratio of the fibrinogen solution to the thrombin solution is 2:1-10:1. This tissue adhesive is used to stick living tissue of a human being or an animal or to close the same.		

(57) 要約

高濃度のフィブリンを均一に形成させ、高い閉鎖効果を付与する組織接着剤が開示される。この組織接着剤は、無菌ガスを用いて混合噴霧塗布され、かつ分離されたフィブリノゲン溶液とトロンビン溶液とからなり、フィブリノゲン溶液とトロンビン溶液との容積比は約2:1~10:1である。この組織接着剤は、ヒトまたは動物の生体組織の接着又は閉鎖のために無菌ガスを用いて混合噴霧塗布される。

情報としての用途のみ

PCTに基づいて公開される国際出願をパンフレット第一頁にPCT加盟国を同定するために使用されるコード

AL	アルバニア	EE	エストニア	LR	リベリア	RU	ロシア連邦
AM	アルメニア	ES	スペイン	LS	レソト	SD	スーダン
AT	オーストリア	FR	フランス	LT	リトアニア	SE	スウェーデン
AU	オーストラリア	GA	ガボン	LU	ルクセンブルグ	SG	シンガポール
AZ	アゼルバイジャン	GB	イギリス	LV	ラトヴィア	SI	スロヴァニア
BB	バルバドス	GE	グルジア	MC	モナコ	SK	スロヴァキア共和国
BE	ベルギー	GH	ガーナ	MD	モルドバ	SN	セネガル
BG	ブルガリア	GN	ギニア	MG	マダガスカル	SZ	スワジランド
BJ	ベナン	GR	ギリシャ	MK	マケドニア	TD	チャド
BR	ブラジル	HU	ハンガリー	UA	ウクライナ	TG	トーゴ
BY	ベラルーシ	IE	アイルランド	ML	マリ	TJ	タジキスタン
CA	カナダ	IS	アイスランド	MN	モンゴル	TM	トルクメニスタン
CF	中央アフリカ共和国	IT	イタリア	MR	モーリタニア	TR	トルコ
CG	コンゴ	JP	日本	MW	マラウイ	TT	トリニダード・トバゴ
CH	スイス	KE	ケニア	MX	メキシコ	UA	ウクライナ
CI	コート・ジボアール	KG	キルギスタン	NE	ニジェール	UG	ウガンダ
CM	カメルーン	KR	朝鮮民主主義人民共和国	NL	オランダ	US	米国
CN	中国	KZ	大韓民国	NO	ノルウェー	UZ	ウズベキスタン共和国
CZ	チェコ共和国	LI	リヒテンシュタイン	NZ	ニュージーランド	VN	ベトナム
DE	ドイツ	LK	スリランカ	PL	ポーランド	YU	ユーゴスラビア
DK	デンマーク			PT	ポルトガル		
				RO	ルーマニア		

Abstract:

An adhesive for tissue capable of uniformly forming a high concentration of fibrin so as to provide a high closing effect is disclosed. The adhesive for tissue comprises a fibrinogen solution and a thrombin solution which solutions are separated from each other. The adhesive is to be mixed and spray coated together with a sterile gas and has a volume ratio of the fibrinogen solution to the thrombin solution of about 2:1 to 10:1. This adhesive is to be sprayed together with a sterile gas for the adhesion or closing of living tissue of a human being or animal.



SPECIFICATION

Title of the Invention:

Tissue Adhesive Suitable for Spray Application


5

Technical Field of the Invention:

The present invention relates to an adhesive for tissue, which is to be used in the form of a two-pack type preparation and which is suitable for the uniform application of the adhesive at a concentration
10 higher than that of an ordinary adhesive. In particular, the present invention relates to an adhesive for tissue (hereinafter referred to as tissue adhesive) suitable for the use in a method wherein a protein solution containing fibrinogen as the essential component and a thrombin solution are sprayed and also suitable for lowering the volume ratio of a
15 thrombin solution to a fibrinogen solution of a high concentration so as to uniformly form fibrin of a high-concentration, whereby obtaining a high closing effect.

Background of the Invention:

20 Fibrinogen is a clotting factor having a very important role in the final stage of the so-called blood-coagulation cascade. In the activation of, for example, the blood clotting system after a damage, soluble fibrinogen is converted, by thrombin, into insoluble fibrin which has an important role of contributing to the hemostasis and curing of a
25 wound. Recently, a tissue adhesive was developed taking advantage of this theory in the final phase of the blood clotting, and it is now used as an



adhesive in place of a suture of a soft organ such as liver or spleen or as a suture assistant in a surgical operation. A tissue adhesive is widely used also in other clinical situation.

For the application of the tissue adhesive to an affected part of the body, a "sequential method" wherein a fibrinogen solution and a thrombin solution are applied alternately to form a laminate coat or a "simultaneous method" wherein both the fibrinogen solution and thrombin solution are applied simultaneously to mix them together was mainly employed. However, the sequential method has a problem in that a major part of the fibrinogen solution flows down prior to the formation of a fibrin gel, and also the simultaneous method has a problem in that the formed fibrin gel is heterogeneous. Therefore, the effect of the tissue adhesive was limited in both the sequential method and simultaneous method.

Recently, a spray method has just started to be spread for solving the above-described problems. In this method, a fibrinogen solution and a thrombin solution in each syringe are simultaneously ejected together with a sterile gas to spray these two solutions in the form of a mist mixture. A preferred example of the devices for this method is described in International Patent Publication (PCT WO94-07420). However, even such a spray method has a problem to be solved for obtaining a complete effect of the tissue adhesive when a strong adhesion and closing effect are demanded in, for example, the treatment of great vessels and also the treatment of air leak in the lungs.

Investigations were made for improving the effect of the tissue adhesive by increasing the concentration of fibrinogen to find that, although the clotting strength and adhesive power of the fibrin gel



obtained by the sequantial method are increased as the final concentration of fibrinogen in the mixture of the two components is increased, they are no more increased even when the final concentration of fibrinogen is increased to about 4 % or higher [see "Kiso to Rinsho" (Basic and Clinical Report), 20, 2399 to 2405 (1986), and 23, 3735 to 3743 (1989)]. However, when the sequential method is employed, the fibrin gel obtained by such a test cannot be uniformly applied. Thus, it cannot be said that the advantage of the increase in the final concentration of fibrinogen has been put to practical use.

Japanese Patent Unexamined Published Application (hereinafter referred to as "J. P. KOKAI") No. Sho 61-293443 discloses a method for increasing the final concentration of fibrinogen in the mixture of the two components by changing the mixing ratio of the fibrinogen solution to the thrombin solution in its specification (in particular, in the "test results" in the detailed description of the Invention). In this specification, it is described that the limiting tensile strength depends on the final concentration of fibrinogen after mixing the two components.

However, in these tests, the adhesive is applied by so-called "mixing method" and, in addition, the final concentration of thrombin in the formation of the fibrin gel after mixing the two components is as low as 1 to 2 units/ml. Such a low thrombin concentration is far apart from the thrombin concentration (250 to 500 units/ml) actually employed in the clinical sites. It is known that particularly when the thrombin concentration is low, the clotting of fibrinogen necessitates a long period of time and, in addition, a sufficient hemostasis effect cannot be obtained in the closing treatment of the tissue. Although a test wherein



the final concentration of thrombin after mixing the two components is as high as 500 units/ml is described therein, it is stated therein that the limiting tensile strength could not be determined. This fact suggests that the tests given in J. P. KOKAI No. Sho 61-293443 are unsuitable for the determination of the effects of the tissue adhesive to be used in a clinical site.

The main object of the invention disclosed in J. P. KOKAI No. Sho 61-293443 is to provide a device for preparing a fibrinogen solution from a freeze-dried preparation previously charged in a syringe, which is capable of shortening the dissolution time without reducing the limiting tensile strength of the adhesive. In this invention, the mixing ratio is varied so that a limiting tensile strength equal to that of an ordinary product (a concentration is 10 % before the mixing) can be obtained even when the concentration of the fibrinogen solution is lowered. Therefore, the concentration described therein is not the practical one, and this invention does not provide any means for adhering a tissue which is suitable for the actual use for particularly obtaining a high effect of closing the wound.

Therefore, the object of the present invention is to provide a tissue adhesive suitable for spray application, which is to be used in the form of a two-pack preparation and which can be used at a high concentration and uniformly sprayed.

Another object of the present invention is to provide a tissue adhesive capable of uniformly forming fibrin of a high concentration to provide a high closing effect.

After intensive investigations made for the purpose of attaining



the above-described objects, and on the basis of an idea that the spray method wherein the fibrinogen solution and thrombin solution can be homogeneously mixed together is the best method for the application of the tissue adhesive, the inventors have found the following fact: for
5 improving the effect of fibrinogen by increasing the final concentration of fibrinogen in the mixture of the two components, it is effective that the concentration of fibrinogen which can be sprayed is made as high as possible and also that the mixing ratio of the fibrinogen solution and thrombin solution is changed. Further, the structure of a device for
10 conducting this method has been made clear, and the present invention capable of providing the tissue adhesive suitable for use in a method wherein a remarkable effect is obtained has been completed.

Disclosure of the Invention:

15 The present invention relates to a tissue adhesive comprising a fibrinogen solution and a thrombin solution which solutions are separate from each other and to be mixed and sprayed together by means of a sterile gas for adhering or closing a wound of a living tissue of a human being or an animal, wherein the volume ratio of the fibrinogen solution to
20 the thrombin solution is about 2:1 to 10:1.

Brief Description of the Drawings:

Fig. 1 is a drawing showing the method for determining the closing effect.

25 Fig. 2 is a graph showing the change in closing effect by changing the mixing ratio in both spray method and sequential method.





Fig. 3 is a plan view of a device suitable for spraying the tissue adhesive of the present invention.

Preferred Embodiments for Practicing the Invention:

5 The object of the present invention is to obtain a high closing effect by changing the mixing volume ratio of the fibrinogen solution to the thrombin solution of 1:1 which was conventionally used in the prior art so as to reduce the volume ratio of the thrombin solution to the fibrinogen solution, so that when both the solutions are sprayed, fibrin
10 of a high concentration is uniformly formed. From this viewpoint, the suitable concentrations of the fibrinogen solution and the thrombin solution are 4 to 15 % (w/v, 40 to 150 mg/ml), preferably 7 to 12 % (w/v, 70 to 120 mg/ml), and 100 to 10,000 units/ml (Japanese Pharmacopoeia or NIH units based on the US Standard Thrombin), preferably 250 to 5,000
15 units/ml (NHI units), respectively. The mixing ratio of them is preferably about 2:1 to 10:1 (volume ratio), particularly 2:1 to 5:1.

 Although it is difficult to mix the two components in a precise mixing ratio other than 1:1 by using the two separate syringes, such a mixing can be conducted preferably by using an application device
20 suitable for the tissue adhesive of the present invention, which is shown in Fig. 3.

 In this device, a syringe containing the fibrinogen solution has an effective stroke having a length equal to that of another syringe containing the thrombin solution, and the cross section of the syringe
25 containing the fibrinogen solution is about 2 to 10 times as large as that of the syringe containing the thrombin solution. By operating the



pistons of both syringes integrally, both solutions in a volume ratio determined according to the cross sections of the two syringes are extruded through a pipe to a sterile gas jet opening in a spray head to form a mist. The adhesive is thus spray coated.

5 The present invention provides a more desirable mode of the tissue adhesive suitable for the spray coating. When a fibrinogen solution is to be sprayed with a spraying device, it was difficult to spray the fibrinogen solution having a concentration of as high as above 10 % (100 mg/ml) in the prior art. However, the viscosity of the fibrinogen
10 solution can be remarkably lowered by adding a viscosity-lowering agent to the solution so that the solution can be sprayed in a suitable manner. Particularly when a high adhesion strength is necessitated, the uniform spraying is made possible by lowering the viscosity even when the fibrinogen content is about 10 % (100 mg/ml) or higher. The object of
15 the invention can be thus attained.

 By increasing the concentration of the fibrinogen solution to be mixed with the thrombin solution, the final concentration of fibrinogen which was increased by changing the mixing ratio is further increased and the effect thereof is further improved. The viscosity-lowering agents
20 which are not particularly limited herein include, for example, guanidino group-containing substances such as arginine and guanidine. Arginine or the like is particularly preferably used. The viscosity-reducing agents are usable either alone or in combination of two or more of them. The amount of the viscosity-reducing agent is preferably 0.1 to 1.0 M,
25 particularly preferably 0.1 to 0.5 M.

 According to the present invention, the tissue adhesive having a



high closing effect can be obtained by uniformly forming fibrin of a high concentration.

The following Test Examples and Working Examples will further illustrate the present invention, which by no means limit the scope of the present invention.

Examples

Test Example 1

The test was conducted by using "Bolheal" [a product of the Chemo-Sero-therapeutic Research Institute] which is a commercial two-component adhesive for living tissue. This preparation had a fibrinogen concentration of 8 % and thrombin concentration of 250 units/ml.

The closing effect was evaluated by means of a device shown in Fig. 1. In the test, five holes having a diameter of 1.2 mm were bored in a cap of a plastic test tube which was then connected with a manometer and a compressing syringe. A tissue adhesive comprising the two solutions in a varied mixing ratio was applied to the cap by the spray method or sequential method. Ten minutes after the formation of the adhesive, air in the tube was compressed with the syringe and the pressure (burst pressure: mmHg) at the moment of starting the air leak through the fibrin gel was recorded. The mixing ratio of the fibrinogen solution to the thrombin solution was 1:1 or 5:1. The amount of the fibrinogen solution used was 0.85 ml in all the cases.

As shown in Fig. 2, when the mixing ratio was changed from 1:1 to 5:1, the burst pressure was remarkably elevated from 287 mmHg to 445 mmHg in the spray method, while it was lowered in the sequential method. The



burst pressure of 445 mmHg obtained by changing the mixing ratio in the spray coating was an extremely high pressure which could not be obtained in the prior art.

5 Test Example 2

The test was conducted by using "Bolheal" [a product of the Chemo-Sero-therapeutic Research Institute] which is a commercial two-component adhesive for living tissues. This preparation had a fibrinogen concentration of 8 % and thrombin concentration of 250 units/ml.

10 The closing effect was evaluated on the basis of the air leak-preventing capacity in the lungs of rats. In the test, a tracheal tube was inserted into the trachea of a rat and fixed therein at one end thereof by the ligation. The other end of the tracheal tube was connected with a cannula, trigonal stopcock, manometer and compressing syringe.

15 After confirming no air leak, the pressure was controlled with the syringe so that the manometer indicated 15 mmHg. A hole having a diameter of 1.2 mm was bored in the lung with a needle, and a tissue adhesive having a given mixing ratio was spray coated on the air leak portion. 10 minutes after the formation of the adhesive, saline was applied to the lung, the

20 pressure was elevated with the syringe, and the pressure (burst pressure: mmHg) under which the air leak of the lung began was recorded. The mixing ratio of the fibrinogen solution to the thrombin solution was 1:1 or 5:1. The amount of the fibrinogen solution used was 0.15 ml in all the cases.

25 As shown in the following Table 1, the burst pressure was remarkably elevated from 27.8 mmHg to 49.4 mmHg by changing the mixing ratio from 1:1 to 5:1.



Table 1

Burst pressure	Order of times of determination									
(mmHg)	1	2	3	4	5	6	7	8	Average $\pm$	S.D.
<u>Mixing ratio</u>										
1:1	16	25	31	32	43	32	20	23	27.8 $\pm$	8.5
5:1	40	64	42	40	67	42	42	58	49.4 $\pm$	11.6

10 Test Example 3

A solution having a coagulating protein concentration of 7.5 toll.
 1 % (w/v) was prepared from fibrinogen prepared by a combination of a
 cold ethanol precipitation method with a method wherein the solubility of
 fibrinogen is lowered by glycine or by a glycine precipitation method
 wherein glycine is used alone. The viscosity (mPa $\cdot$ s) of each solution
 was determined at 37°C to find that a high viscosity resulted depending on
 the coagulating protein concentration. Particularly when the coagulating
 protein concentration was 11.1 %, the viscosity was as high as 152.2 mPa
 $\cdot$ s. However, when arginine was added to the 11.1% solution so that the
 final arginine concentration would be 0.1 to 0.5 M, the viscosity became
 77.4 to 84.2 mPa $\cdot$ s. This fact proved the viscosity-lowering effect of
 arginine. The results were as shown in the following Table 2.



Table 2

	Arginine conc. (M)	Coagulating protein conc. (%)	Viscosity of solution (mPa · s)
5	0.0	7.5	18.2
	0.0	7.9	24.2
	0.0	8.8	36.2
	0.0	9.7	61.5
	0.0	11.1	152.2
10	0.1	11.1	82.8
	0.2	11.1	84.2
	0.3	11.1	77.4
	0.4	11.1	77.4
	0.5	11.1	78.5

15

Example 1

An example of the application of the tissue adhesive of the present invention by means of a suitable applying device will be described below with reference to the drawing.

20 Fig. 3 is a plan view of a device suitable for spraying the tissue adhesive of the present invention. The device for spraying the tissue adhesive is composed of a syringe (1) containing the fibrinogen solution, a syringe (2) containing the thrombin solution, a syringe-holding means (3) for fixing each syringe at its barrel (5 or 6) part, an integrally
 25 operating means (4) placed at the end of a plunger (7 or 8) of each syringe for operating the plunger (7 or 8), integrally, and a spray head



(9) at the syringe ends.

As shown in Fig. 3, the cross section of the syringe (1) is larger than that of the syringe (2). In an embodiment shown in Fig. 3, the cross section ratio is 5:1 and, therefore, the volume ratio is also 5:1. The effective stroke, i.e. the distances from the end faces at the exits (17 or 18) to the inserted pistons (15 or 16) of the two syringes (1 and 2) are equal.

A sterile gas is introduced into a spray head (9) through a sterile gas-feeding passage (13), and jetted through a sterile gas-jet opening (14). At the same time, an integrally operating means (4) for the syringe (1) containing the fibrinogen solution and the syringe (2) containing the thrombin solution is pressed to extrude both solutions, in a volume ratio which varies depending on the cross sections of the syringes, in the form of a mist through the passages in the spray head (9) and tubes (11 and 12). The adhesive is thus sprayed.

The syringes (1 and 2) are usually made from glass or a transparent synthetic resin such as a polypropylene or a polycarbonate. The syringes (1 and 2) are each composed of a barrel (5 or 6) having a narrowed part to be connected with the spray head (9) and a smoothly slidable plunger (7 or 8) inserted into the barrel (5 or 6).


The sterile gas passed through an air filter is fed into the spray head (9) through the sterile gas-feeding passage (13), and then jetted through the sterile gas-jet opening (14). In the spray head (9), the tubes (11 and 12) for feeding the fibrinogen solution and thrombin solution are arranged from syringe-connecting ports (10) toward the sterile gas-jet opening (14). Although the materials for the spray head



(9) are not particularly limited, they are usually soft resins such as vinyl chloride resin, polyethylene, polyesters and polypropylene, and metals having a high processability. The tubes (11 and 12) are made of Teflon, vinyl chloride resin, a metal or the like.

5 The syringe-holding means (3) is to fix the syringes (1) and (2), integrally. The shapes of the syringe-holding means (3) can be various, and the shape shown in Fig. 3 is one of them. In one face of the syringe-holding means (3), two grooves having shapes corresponding to the shapes of the outer walls of the barrels (5 and 6) are formed in parallel.
10 The depth of the grooves is larger than the radius of the cross section of the barrel (5 or 6). Therefore, the inlet of the groove is narrow so that when the barrel (5 or 6) is fixed into the groove, the barrel (5 or 6) will be kept by the grooved wall.

15 The integrally operating means (4) fixes the pressing parts of the two plungers (7 and 8) so as to integrally move these plungers (7 and 8) in the barrels (5 and 6). The shapes of the integrally operating means (4) can be various, and the shape shown in Fig. 3 is one of them. Two grooves parallel to each other and keeping plates vertical to the grooves are integrally molded for fixing the pressing parts of the plungers (7
20 and 8). The shape of the grooves is almost similar to that of the grooves of the syringe-holding means (3) so that each pressing part is fixed in the groove and thereby kept therein. A gap is provided between the groove and the keeping plate, which varies depending on the pressing part of the plunger (7 or 8). The syringe-holding means (3) and the
25 integrally operating means (4) are usually made from a synthetic resin which is preferably polyethylene, polypropylene, acrylonitrile/



butadiene/styrene copolymer or a polycarbonate.

5 The spray coating adhesive for tissue of the present invention is practically used as follows: The syringe (1) filled with the fibrinogen solution and the syringe (2) filled with the thrombin solution are fixed in the syringe-holding means (3). The volume ratio of the fibrinogen solution to the thrombin solution in the syringes (1 and 2) varies depending on the cross section of each syringe. A pair of the syringes (1 and 2) are mounted in the spray head (9). The pressure of the sterile gas to be jetted is controlled, and the gas is then jetted. Then, the integrally operating means (4) is slowly pressed with the thumb to simultaneously apply the fibrinogen solution and the thrombin solution in a mist form, by means of the sterile gas.

Industrial Utilization:

15 The tissue adhesive of the present invention is useful for the adhesion or closing of living tissue of a human being or an animal, when a strong adhesion and closing effect are demanded in, for example, the treatment of great vessels and also the treatment of air leak in the lungs.



What is claimed is:

1. An adhesive for tissue comprising a fibrinogen solution and a thrombin solution which solutions are separated from each other, said adhesive being to be mixed and sprayed together with a sterile gas for the adhesion or closing of living tissue of a human being or animal, wherein the volume ratio of the fibrinogen solution to the thrombin solution is about 2:1 to 10:1.

2. The adhesive of claim 1, wherein the volume ratio of the fibrinogen solution to the thrombin solution is 2:1 to 5:1.

3. The adhesive of claim 1, wherein the fibrinogen solution has a concentration of 4 to 15 % (w/v, 40 to 150 mg/ml).

4. The adhesive of claim 3, wherein the fibrinogen solution has a concentration of 7 to 12 % (w/v, 70 to 120 mg/ml).

5. The adhesive of claim 1, wherein the thrombin solution has a concentration of 100 to 10,000 units/ml (NIH units).

6. The adhesive of claim 5, wherein the thrombin solution has a concentration of 250 to 5,000 units/ml (NIH units)

7. The adhesive of claim 1, wherein the fibrinogen solution contains at least one viscosity-lowering agent.

8. The adhesive of claim 7, wherein the viscosity-lowering agent is arginine.

9. The adhesive of claim 8 which contains 0.1 to 1.0 M of arginine.

10. The adhesive of claim 9 which contains 0.1 to 0.5 M of arginine.




FIG. 1




FIG. 2




FIG. 3

